Insilico Medicine

#insilicomeds, #drugdiscovery, #ai, #oncology, #RL, #DL #aging, #longevity #biologics #LLMS #AIDD

Founded 2014

Boston, United States 288 employees IPO Total: $764.50M AI, Biotechnology +2

General Information

Company Name Insilico Medicine

Founded Year 2014

Location

Boston, United States

Employees 288

Industries AI, Biotechnology, Health Care +1

Funding Stage IPO

Business Model B2B, SaaS, DaaS

Revenue Model Licensing, Subscription, Service Fee

Offices as of Sep 2026

Boston, United States New York, United States New Territories, Hong Kong S.a.r.

Social

BounceWatch is an independent company data service, not affiliated with Insilico Medicine. To contact Insilico Medicine, visit insilico.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Insilico Medicine compare?

A PDF of Insilico Medicine and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Insilico Medicine soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Oct 01, 2026

Insilico Medicine announced a partnership in co-convening the ARDD 2026 event, which opened today.

Feature Release Sep 29, 2026

Insilico Medicine has launched an AI-powered method for retrosynthesis rule generation, integrating their Cheminformatics Engine, MolTools, with the Kimi-K3 model.

Event Participation Sep 28, 2026

Insilico Medicine's CEO, Alex Zhavoronkov, presented on AI-Driven IPF Candidate Rentosertib in Paris, showcasing its potential for Biological Age Reversal.

Regulatory Approval Sep 22, 2026

Insilico Medicine's investigational drug, ISM6331, has received FDA Fast Track and Orphan Drug Designations for mesothelioma.

Product Launch Sep 21, 2026

Insilico Medicine unveiled MMAI Gym for Science, a post-training environment delivering up to 10x performance gains for drug discovery.

Award Received Sep 17, 2026

Insilico Medicine's research on aging and AI received significant recognition by being featured on the cover of Cell, a prestigious scientific journal.

+3 more signals in last 30 days

Get alerts when Insilico Medicine shows new signals

AI Insight

Bounce Watch AI

3 weeks ago

Insilico Medicine is demonstrating accelerated growth and clinical validation, evidenced by a 287.2% YoY revenue increase in H1 2026 and the AI-designed drug Rentosertib progressing to Phase 3, alongside a Nature Biotechnology publication highlighting its biological age-reversal potential. Strategically, the company is rapidly expanding its pipeline with new candidates and enhancing its core AI drug discovery platform through specialist LLM launches and technology integrations, solidifying its post-IPO market position and commercialization drive.

Signal Types

Traction Milestone Product Launch Business Development Research Publication

Strategic Labels

Clinical Acceleration AI Platform Enhancement Commercialization Drive

Next Move: Commercialization

Impact: 9/10

Ideal For: Growth Equity & Biotech VCs — Post-IPO / Longevity Focus

About Insilico Medicine

Insilico Medicine is a clinical stage biotech firm utilizing cutting-edge AI technology to streamline drug discovery processes. Founded in 2014, the company is headquartered in the United States and operates at the intersection of AI, biotechnology, health care, and pharmaceuticals.

The company's innovative approach leverages advanced AI systems, including deep generative models and reinforcement learning, to connect biology, chemistry, and clinical trial analysis. This technological prowess is instrumental in discovering novel drug targets and generating molecular structures optimized for various disease areas such as cancer, fibrosis, and aging-related conditions.

Insilico Medicine received its last investment round of $293.00M in an IPO on 01 December 2025, which underscores robust investor confidence in its strategic direction. With a mission to deliver groundbreaking pharmaceutical solutions, Insilico Medicine remains a promising entity in the biotech space, poised to significantly impact the way contemporary medicine is practiced.

Taxonomy: Clinical Stage Biotech, Generative AI, AI Drug Discovery, Deep Generative Models, Reinforcement Learning, Novel Molecular Structures, Cancer Treatment, Aging-related Diseases, Neuroscience, Biologics, Digital Medicine, Nutraceuticals, Bioinformatics, Generative Adversarial Networks, Internal Drug Programs

Services & Products

AI-driven drug discovery

Therapeutic program development

Biological and chemical research tools

Disease modeling and target identification

Generative AI software solutions

Target Customers

Pharmaceutical companies Biotech firms Medical researchers Healthcare institutions Academic research bodies

Funding Rounds & Investors (13)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
IPO	$293.00M	-		01 Dec 2025
Series E	$23.00M	4	Prosperity7 Ventures, Value Partners +2	01 Jun 2025
Series E	$100.00M	2	Value Partners, Shanghai Pudong Venture Capital	01 Jan 2025
Series D	$35.00M	1	Prosperity7 Ventures	01 Aug 2022
Series C	$255.00M	19	Eight Roads Ventures, Lilly Asia Ventures +17	01 Jun 2021
Series B	Undisclosed	-		01 Apr 2020
Series B	$37.00M	9	Eight Roads Ventures, F-Prime Capital +7	01 Sep 2019
Series A	$6.00M	4	Bold Capital Partners, Juvenescence +2	01 Jun 2018
Series A	$4.00M	-		01 Jul 2017
Early VC	$10.00M	2	A-Level Capital, Mellon Ventures	01 Feb 2017

View All 13 Funding Rounds

Latest News

View All

Insilico says its AI-designed lung drug lowered biological age markers in a 42-patient trial

Thenextweb Sep 07, 2026

The company that built TikTok’s algorithm is now designing drugs for diseases pharma called undrugga... — Thenextweb

The company that built TikTok’s algorithm is now designing drugs for diseases pharma called undruggable

Thenextweb May 02, 2026

Can AI outperform doctors? Experts weigh the pros and cons

Cnbc Apr 29, 2026

AI can screen 15 million molecules in a day. It still can’t cure Alzheimer’s.

Thenextweb Apr 11, 2026

Oil's record month, TSA pay, the Pokémon card resale market and more in Morning Squawk

Cnbc Mar 30, 2026

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

Cnbc Mar 29, 2026

Insilico Medicine Alternatives & Competitors

View All Alternatives

Insilico Medicine vs

Standigm Korea South

The workflow AI drug discovery company

Growth

23 employees

AI, Biotechnology

Insilico Medicine vs

Absci United States

Unlocking differentiated biology with generative AI

IPO

159 employees

AI, Biopharma

Insilico Medicine vs

Syntekabio Inc. United States

AI Platform for Drug Discovery & Precision Medicine (226330:KOSDAQ)

Series C

36 employees

Biotechnology, Health Care

View all alternatives

FAQ About Insilico Medicine

#insilicomeds, #drugdiscovery, #ai, #oncology, #RL, #DL #aging, #longevity #biologics #LLMS #AIDD

Insilico Medicine was founded in 2014.

Insilico Medicine is headquartered in Boston, United States. As of Sep 2026, it also has offices in New York, United States and New Territories, Hong Kong S.a.r..

Insilico Medicine operates in AI, Biotechnology, Health Care and Pharmaceutical. Its work centres on Clinical Stage Biotech, Generative AI, AI Drug Discovery and Deep Generative Models. Its customers include Pharmaceutical companies, Biotech firms and Medical researchers.

Insilico Medicine has a B2B, SaaS and DaaS business model. Its revenue comes from Licensing, Subscription and Service Fee.

Insilico Medicine has approximately 288 employees.

Insilico Medicine has completed 13 funding rounds, raising a total of $764.50M. The latest funding stage is IPO.

Insilico Medicine offers: AI-driven drug discovery, Therapeutic program development, Biological and chemical research tools, Disease modeling and target identification, Generative AI software solutions.

Top alternatives and competitors to Insilico Medicine include Standigm, Absci, Syntekabio Inc., Rubedo Life Sciences, Sensei Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Insilico Medicine and Standigm are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Insilico Medicine, https://bouncewatch.com/company/insilico-medicine, updated 24 September 2026. When citing, please name BounceWatch and link this page.

Insilico Medicine

General Information

Discover More

What changed at Insilico Medicine recently?

AI Insight

About Insilico Medicine

Services & Products

Target Customers

Funding Rounds & Investors (13)

Latest News

Insilico Medicine Alternatives & Competitors

FAQ About Insilico Medicine